- Home
- ATIF vs ADXN Comparison
ATIF vs ADXN Comparison
Compare ATIF & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATIF
- ADXN
- Stock Information
- Founded
- ATIF 2015
- ADXN 2002
- Country
- ATIF United States
- ADXN Switzerland
- Employees
- ATIF N/A
- ADXN N/A
- Industry
- ATIF Professional Services
- ADXN Biotechnology: Pharmaceutical Preparations
- Sector
- ATIF Consumer Discretionary
- ADXN Health Care
- Exchange
- ATIF Nasdaq
- ADXN Nasdaq
- Market Cap
- ATIF 9.8M
- ADXN 11.3M
- IPO Year
- ATIF 2019
- ADXN N/A
- Fundamental
- Price
- ATIF $0.86
- ADXN $10.30
- Analyst Decision
- ATIF
- ADXN Strong Buy
- Analyst Count
- ATIF 0
- ADXN 1
- Target Price
- ATIF N/A
- ADXN $30.00
- AVG Volume (30 Days)
- ATIF 214.7K
- ADXN 22.8K
- Earning Date
- ATIF 12-13-2024
- ADXN 11-11-2024
- Dividend Yield
- ATIF N/A
- ADXN N/A
- EPS Growth
- ATIF N/A
- ADXN N/A
- EPS
- ATIF N/A
- ADXN 0.05
- Revenue
- ATIF $500,000.00
- ADXN $960,641.00
- Revenue This Year
- ATIF N/A
- ADXN N/A
- Revenue Next Year
- ATIF N/A
- ADXN N/A
- P/E Ratio
- ATIF N/A
- ADXN $1.75
- Revenue Growth
- ATIF N/A
- ADXN N/A
- 52 Week Low
- ATIF $0.58
- ADXN $5.00
- 52 Week High
- ATIF $1.50
- ADXN $27.90
- Technical
- Relative Strength Index (RSI)
- ATIF 46.75
- ADXN 54.08
- Support Level
- ATIF $0.85
- ADXN $10.04
- Resistance Level
- ATIF $1.50
- ADXN $10.81
- Average True Range (ATR)
- ATIF 0.18
- ADXN 0.59
- MACD
- ATIF -0.01
- ADXN 0.04
- Stochastic Oscillator
- ATIF 15.82
- ADXN 70.88
About ATIF ATIF Holdings Limited
ATIF Holdings Ltd is a consulting company. It provides financial and advisory services to small and medium-sized enterprises and also to individual customers and families. The firm also offers Pre-IPO's, and Post-IPO's services. It operates in one operating segment which is the consulting service business. It generates the majority of its revenue from the USA.
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment which is the discovery, development and commercialization of small-molecule pharmaceutical products.